CTRI/2023/07/055481尚未招募2 期
The study of efficacy and clinical safety of Aragwadh majjawith granules in constipation during pregnancy - NI
Soni Yesha0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. All antenatal mothers of second and third trimesters of all age groups.
- •2. Patients having Haemoglobin more than 10mg/dl.
排除标准
- •1. Pregnant women having GDM.
研究者
相似试验
进行中（未招募）
不适用
Evaluation of efficacy and clinical benefit of agomelatine (25 to 50 mg/day) over a 6-month treatment period in patients with Major Depressive Disorder.A randomised, double-blind, international multicentre study with parallel groups versus duloxetine (60 mg/day).Twenty-four weeks of treatment.MedDRA version: 11.0Level: LLTClassification code 10057840Term: <Manually entered code. Term in E.1.1>Major Depressive DisorderEUCTR2008-004642-92-HUInstitut de Recherches Internationales Servier400
进行中（未招募）
不适用
Evaluation of efficacy and clinical benefit of agomelatine (25 to 50 mg/day) over a 6-month treatment period in patients with Major Depressive Disorder. A randomised, double blind, international multicentre study with parallel groups versus duloxetine (60 mg/day). Twenty-four weeks of treatment. - NDMedDRA version: 9.1Level: LLTClassification code 10057840Term: Major depressionMajor Depressive DisorderEUCTR2008-004642-92-ITINSTITUT DE RECHERCHES INTERNATIONALES SERVIER400
进行中（未招募）
不适用
Evaluation of efficacy and clinical benefit of agomelatine (25 to 50 mg/day) over a 6-month treatment period in patients with Major Depressive Disorder.A randomised, double-blind, international multicentre study with parallel groups versus duloxetine (60 mg/day).Twenty-four weeks of treatment.Major Depressive DisorderEUCTR2008-004642-92-PTInstitut de Recherches Internationales Servier400
进行中（未招募）
不适用
Evaluation of efficacy and clinical benefit of agomelatine (25 to 50 mg/day) over a 6-month treatment period in patients with Major Depressive Disorder.A randomised, double-blind, international multicentre study with parallel groups versus duloxetine (60 mg/day).Twenty-four weeks of treatment.Major Depressive DisorderEUCTR2008-004642-92-GBInstitut de Recherches Internationales Servier400
已完成
3 期
Evaluation of efficacy and clinical benefit of agomelatine in patients with major depressive disorder compared to serotonin-norepinephrine reuptake inhibitor (SNRI)Major depressive disorderMental and Behavioural DisordersDepressive episodeISRCTN96725312Institut de Recherches Internationales Servier (France)418